LABZIENT Trademark

Trademark Overview


On Monday, July 22, 2024, a trademark application was filed for LABZIENT with the United States Patent and Trademark Office. The USPTO has given the LABZIENT trademark a serial number of 98660690. The federal status of this trademark filing is APPROVED FOR PUBLICATION as of Thursday, May 29, 2025. This trademark is owned by Abzena (UK) Limited. The LABZIENT trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Scientific and technological services, namely, scientific research in the field of cell lines, cell cultures, proteins, and antibodies for use in the development and manufacture of vaccines and pharmaceutical preparations; industrial analysis and research in the field of cell lines, cell cultures, proteins, and antibodies for use in the development and manufacture of vaccines and pharmaceutical preparations; new product design services; pharmaceutical research services; pharmaceutical product evaluation; inspection of pharmaceuticals; testing of pharmaceuticals; pharmaceutical drug development services; development of pharmaceutical preparations and medicines; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; provision of scientific information in the field of vaccines, pharmaceuticals, and in the field of cell lines, proteins, and antibodies for use in the manufacture and development of pharmaceuticals and vaccines; provision of...
labzient

General Information


Serial Number98660690
Word MarkLABZIENT
Filing DateMonday, July 22, 2024
Status680 - APPROVED FOR PUBLICATION
Status DateThursday, May 29, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesScientific and technological services, namely, scientific research in the field of cell lines, cell cultures, proteins, and antibodies for use in the development and manufacture of vaccines and pharmaceutical preparations; industrial analysis and research in the field of cell lines, cell cultures, proteins, and antibodies for use in the development and manufacture of vaccines and pharmaceutical preparations; new product design services; pharmaceutical research services; pharmaceutical product evaluation; inspection of pharmaceuticals; testing of pharmaceuticals; pharmaceutical drug development services; development of pharmaceutical preparations and medicines; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; provision of scientific information in the field of vaccines, pharmaceuticals, and in the field of cell lines, proteins, and antibodies for use in the manufacture and development of pharmaceuticals and vaccines; provision of toxicological research information; toxicology research services, namely, assessing toxicological information in relation to risks; chemical research, namely, assessing chemical information in relation to risks; none of the aforementioned services relating to finished pharmaceutical products administered to patients for the treatment of Parkinson's disease or other diseases or disorders of the central nervous system

Classification Information


International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateMonday, July 22, 2024
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameAbzena (UK) Limited
Party Type10 - Original Applicant
Legal Entity Type24 - NOT AVAILABLE
AddressBabraham, Cambridge CB223AT
GB

Trademark Events


Event DateEvent Description
Wednesday, January 15, 2025NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, January 30, 2025ASSIGNED TO EXAMINER
Monday, July 22, 2024NEW APPLICATION ENTERED
Monday, February 3, 2025NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, February 3, 2025NON-FINAL ACTION E-MAILED
Monday, February 3, 2025NON-FINAL ACTION WRITTEN
Wednesday, April 23, 2025CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, April 23, 2025TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, April 23, 2025TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, May 29, 2025APPROVED FOR PUB - PRINCIPAL REGISTER